Protalix BioTherapeutics
PLX
33 hedge funds and large institutions have $8.24M invested in Protalix BioTherapeutics in 2021 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 12 increasing their positions, 5 reducing their positions, and 14 closing their positions.
140% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 5
13% more call options, than puts
Call options by funds: $2.86M | Put options by funds: $2.53M
10.43% less ownership
Funds ownership: 19.94% → 9.51% (-10%)
13% less funds holding
Funds holding: 38 → 33 (-5)
36% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 14
79% less capital invested
Capital invested by funds: $39.4M → $8.24M (-$31.1M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$6.41M |
| 2 |
Walleye Capital
New York
|
+$1.19M |
| 3 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
+$841K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$616K |
| 5 |
Walleye Trading
New York
|
+$465K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVH
Psagot Value Holdings
Tel Aviv,
Israel
|
-$10.6M |
| 2 |
BCM
Burrage Capital Management
Boston,
Massachusetts
|
-$9.48M |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$5.37M |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$1.99M |
| 5 |
Renaissance Technologies
New York
|
-$1.64M |
PLX Hedge Fund Activity: Q2 2021 in Review
33 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q2 2021, worth a combined $8.24M — down 79% from $39.4M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of PLX and 9 opened new positions — a net loss of 5 holders — while 5 trimmed existing stakes and 12 added.
The largest buyer was Morgan Stanley, adding an estimated $6.41M. The largest seller was Psagot Value Holdings, cutting an estimated $10.6M.
- 33 institutional investors held Protalix BioTherapeutics (PLX) as of Q2 2021, down from 38 in Q1 2021.
- Funds reported $8.24M of Protalix BioTherapeutics stock for Q2 2021, down 79% quarter-over-quarter.
- 9 funds opened new Protalix BioTherapeutics positions in Q2 2021 and 14 closed out, a net change of -5 holders.
- The largest Protalix BioTherapeutics buyer in Q2 2021 was Morgan Stanley, an estimated $6.41M added.
- The largest Protalix BioTherapeutics seller in Q2 2021 was Psagot Value Holdings, an estimated $10.6M sold.
Based on aggregated 13F filings for Q2 2021.